Structure-Based Approach for the Prediction of Mu-Opioid Binding Affinity of Unclassified Designer Fentanyl-Like Molecules
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Swedish Code of Statutes
1. ------IND- 2018 0506 S-- EN- ------ 20190508 --- --- FINAL Swedish Code of Statutes Ordinance amending the Ordinance (1999:58) banning certain products SFS 2018:1587 that are harmful to health Published Issued on 4 October 2018 on 9 October 2018 The Government hereby lays down1 that the annex to the Ordinance (1999:58) prohibiting certain products that are harmful to health shall read as set out below. ___________ This ordinance shall enter into force on 12 November 2018. On behalf of the government ANNIKA STRANDHÄLL Kjell Rempler (Ministry of Health and Social Affairs) 1 See Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services. 2 Annex SFS 2018:1587 List of products to be regarded as products that are harmful to health in accordance with the Ordinance prohibiting certain products that are harmful to health N-methyl-1-(3,4-methylenedioxyphenyl)-2-butylamine (MBDB) 1-(3,4-methylenedioxyphenyl)-2-butylamine (BDB) 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DiPT) 5-methoxy-alphamethyltryptamine (5-MeO-AMT) 2,5-dimethoxy-4-ethylphenethylamine (2C-E) alpha-methyltryptamine (AMT) 2,5-dimethoxy-4-chlorophenethylamine (2C-C) 2,5-dimethoxy-4-methylphenethylamine (2C-D) 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT) gamma-butyrolactone (GBL) 1,4-butanediol (1,4-BD) 4-acetoxy-N,N-methylisopropyltryptamine -
Recommended Methods for the Identification and Analysis of Fentanyl and Its Analogues in Biological Specimens
Recommended methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Recommended Methods for the Identification and Analysis of Fentanyl and its Analogues in Biological Specimens MANUAL FOR USE BY NATIONAL DRUG ANALYSIS LABORATORIES UNITED NATIONS Vienna, 2017 Note Operating and experimental conditions are reproduced from the original reference materials, including unpublished methods, validated and used in selected national laboratories as per the list of references. A number of alternative conditions and substitution of named commercial products may provide comparable results in many cases. However, any modification has to be validated before it is integrated into laboratory routines. ST/NAR/53 Original language: English © United Nations, November 2017. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. Mention of names of firms and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. Acknowledgements The Laboratory and Scientific Section of the UNODC (LSS, headed by Dr. Justice Tettey) wishes to express its appreciation and thanks to Dr. Barry Logan, Center for Forensic Science Research and Education, at the Fredric Rieders Family Founda- tion and NMS Labs, United States; Amanda L.A. -
Understanding and Challenging the Drugs: Chemistry and Toxicology
UNDERSTANDING AND CHALLENGING THE DRUGS: CHEMISTRY AND TOXICOLOGY Presenter: • Dr. Jasmine Drake, Graduate Program Director and Assistant Professor, Administration of Justice Department, Barbara Jordan-Mickey Leland School of Public Affairs, Texas Southern University NACDL Training Defending Drug Overdose Homicides in Pennsylvania Penn State Harrisburg, Middletown, PA November 6th, 2019 11:30- 12:45 p.m. Understanding & Challenging the Drugs: Chemistry & Toxicology Dr. Jasmine Drake, Forensic Science Learning Laboratory, Texas Southern University I. Opioid Drug Classifications A. Types of Opioids B. Classic vs. Synthetic C. Toxicology of Opioids 1) How opioids interact with the body 2) Addiction (psychological vs. physiological II. New Classes of Drugs A. Emerging Threats B. Potency III. National Trends in Opioid Overdose Deaths in the U.S. A. Based on State B. Ethnicity C. Drug-Type (prescription vs. fentanyl vs. heroin) IV. Trends of Opioid Overdose Deaths in Philadelphia A. Based on Ethnicity B. Drug Type (prescription vs. fentanyl vs. heroin) V. Legal Considerations to the Opioid Epidemic A. Punitive Measures vs. Rehabilitative Treatment B. Progressive Jurisdictions Nationwide C. New Legal Measures in Philadelphia VI. Toxicology Reports A. What’s in the report? B. Key Aspects of the Tox Report C. Terminology D. Evaluating and Interpreting the data? E. Questions and considerations. VII. Conclusion and Discussion A. Case Specific Examples B. Sample Toxicology Reports The Opioid Epidemic: What labs have to do with it? Ewa King, Ph.D. Associate Director of Health RIDOH State Health Laboratories Analysis. Answers. Action. www.aphl.org Overview • Overdose trends • Opioids and their effects • Analytical testing approaches • Toxicology laboratories Analysis. Answers. Action. -
UNODC, Synthetic Drugs in East and Southeast Asia
Synthetic Drugs in East and Southeast Asia Latest developments and challenges May 2020 Global SMART Programme Copyright © 2020, United Nations Office on Drugs and Crime (UNODC). This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. UNODC would appreciate receiving a copy of any publication that uses this publication as a source. Acknowledgements This report was prepared by the Global Synthetic Monitoring: Analyses, Reporting and Trends (SMART) Programme, Laboratory and Scientific Section with the support of the UNODC Regional Office for Southeast Asia and the Pacific. Supervision, direction and review Justice Tettey, Chief, Laboratory and Scientific Section Jeremy Douglas, Regional Representative, Southeast Asia and the Pacific Research and drafting Martin Raithelhuber, Illicit Synthetic Drugs Expert Tun Nay Soe, Inter-regional Programme Coordinator Inshik Sim, Drug Programme Analyst, Southeast Asia and the Pacific Joey Yang Yi Tan, Junior Professional Officer in Drug Research Graphic design and layout Akara Umapornsakula, Graphic Designer Administrative support Jatupat Buasipreeda, Programme Assistant The present report also benefited from the expertise and valuable contributions of UNODC colleagues in the Laboratory and Scientific Section and the Regional Office for Southeast Asia and the Pacific, including Tsegahiwot Abebe Belachew, Rebecca Miller, Reiner Pungs, and John Wojcik. Disclaimer This report has not been formally edited. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of UNODC or the Secretariat of the United Nations concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. -
UCSF UC San Francisco Previously Published Works
UCSF UC San Francisco Previously Published Works Title Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review Permalink https://escholarship.org/uc/item/8xh0s7nf Authors Armenian, Patil Vo, Kathy Barr-Walker, Jill et al. Publication Date 2017-10-01 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review Patil Armenian, Kathy Vo, Jill Barr-Walker, Kara Lynch University of California, San Francisco-Fresno and University of California, San Francisco Keywords: opioid, synthetic opioids, fentanyl, fentanyl analog, carfentanil, naloxone Abbreviations: 4-ANPP: 4-anilino-N-phenethyl-4-piperidine; ANPP 4Cl-iBF: 4-chloroisobutyryfentanyl 4F-iBF: 4-fluoroisobutyrfentanyl AEI: Advanced electronic information AMF: alpha-methylfentanyl CBP: US Customs and Border Protection CDC: Centers for Disease Control CDSA: Controlled Drug and Substance Act (Canada) CNS: central nervous system DEA: US Drug Enforcement Agency DTO: Drug trafficking organization ED: Emergency department ELISA: enzyme-linked immunosorbent assay EMCDDA: European Monitoring Centre for Drug and Drug Addiction FDA: US Food and Drug Administration GC-MS: gas chromatography mass spectrometry ICU: intensive care unit IN: intranasal IV: intravenous LC-HRMS: liquid chromatography high resolution mass spectrometry LC-MS/MS: liquid chromatography tandem mass spectrometry MDA: United Kingdom Misuse of Drugs Act NPF: non-pharmaceutical fentanyl THF-F: tetrahydrofuranfentanyl US: United States USPS: US Postal Service UNODC: United Nations office on drugs and crime 1. Introduction The death rate due to opioid analgesics nearly quadrupled in the US from 1999 to 2011 and was responsible for 33,091 deaths in 2015 (CDC, 2014; Rudd et al., 2016). -
Comprehensive Multi-Analytical Screening Of
COMPREHENSIVE MULTI-ANALYTICAL SCREENING OF DRUGS OF ABUSE, INCLUDING NEW PSYCHOACTIVE SUBSTANCES, IN URINE WITH BIOCHIP ARRAYS APPLIED TO THE EVIDENCE ANALYSER Darragh J., Keery L., Keenan R., Stevenson C., Norney G., Benchikh M.E., Rodríguez M.L., McConnell R. I., FitzGerald S.P. Randox Toxicology Ltd., Crumlin, United Kingdom e-mail: [email protected] Introduction Biochip array technology allows the simultaneous detection of multiple drugs from a single undivided sample, which This study summarises the analytical performance of three different biochip arrays applied to the screening of increases the screening capacity and the result output per sample. Polydrug consumption can be detected and by acetylfentanyl, AH-7921, amphetamine, barbiturates, benzodiazepines (including etizolam and clonazepam), incorporating new immunoassays on the biochip surface, this technology has the capacity to adapt to the new trends benzoylecgonine/cocaine, benzylpiperazines, buprenorphine, cannabinoids, carfentanil, dextromethorphan, fentanyl, in the drug market. furanylfentanyl, meprobamate, mescaline, methamphetamine, methadone, mitragynine, MT-45, naloxone, ocfentanyl, opioids, opiates, oxycodone, phencyclidine, phenylpiperazines, salvinorin, sufentanil, synthetic cannabinoids (JWH-018, UR-144, AB-PINACA, AB-CHMINACA), synthetic cathinones [mephedrone, methcathinone, alpha- pyrrolidinopentiophenone (alpha-PVP)], tramadol, tricyclic antidepressants, U-47700, W-19, zolpidem. Methodology Three different biochip arrays were used (DOA ULTRA, -
Critical Review Report: CROTONYLFENTANYL
Critical Review Report: CROTONYLFENTANYL Expert Committee on Drug Dependence Forty-second Meeting Geneva, 21-25 October 2019 This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization 42nd ECDD (2019): Crotonylfentanyl © World Health Organization 2019 All rights reserved. nd This is an advance copy distributed to the participants of the 42 Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use. -
Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. -
TESTIMONY of CASEY OWEN DURST Director of Field Operations
TESTIMONY OF CASEY OWEN DURST Director of Field Operations Baltimore Field Office Office of Field Operations U.S. Customs and Border Protection Department of Homeland Security For a Hearing BEFORE U.S. House of Representatives Committee on Homeland Security Subcommittee on Oversight and Management Efficiency ON “Combating Opioid Smuggling” June 19, 2018 Harrisburg, Pennsylvania Introduction Chairman Perry, Ranking Member Correa, and distinguished Members of the Subcommittee, thank you for the opportunity to appear today to discuss the role of U.S. Customs and Border Protection (CBP) in combating the flow of opioids, including synthetic opioids such as fentanyl, into the United States. The opioid crisis is one of the most important, complex, and difficult challenges our Nation faces today, and was declared a National Emergency by President Donald Trump in October of last year.1 As America’s unified border agency, CBP plays a critical role in preventing illicit narcotics, including opioids, from reaching the American public. CBP leverages targeting and intelligence- driven strategies, and works in close coordination with our partners as part of our multi-layered, risk-based approach to enhance the security of our borders and our country. This layered approach reduces our reliance on any single point or program, and extends our zone of security outward, ensuring our physical border is not the first or last line of defense, but one of many. Opioid Trends, Interdictions, and Challenges In Fiscal Year (FY) 2018 to-date, the efforts of Office of Field Operations (OFO) and U.S. Border Patrol (USBP) personnel resulted in the seizure of more than 545,000 lbs. -
NPS-Related Deaths: Perspective from the EU
New Psychoactive Substances (NPS): the EU Early Warning System (EWS) perspective Rachel Christie, PhD – Action on new drugs, Risks to public safety and security unit, EMCDDA CADAP Regional Conference on new psychoactive substances, 6 February 2019, Bishkek, Kyrgyzstan Historical perspective: the future of drugs of abuse? In 1988 Henderson made some predictions about the future drugs of abuse….. • Future drugs of abuse will be synthetics • Synthesised from readily available precursors • Derivatives of pharmaceuticals • Very potent • Often very selective • Marketed very cleverly Henderson GL. Designer drugs: past history and future prospects. Journal of Forensic Science. 1988 Mar 2 1;33(2):569-75 The future of drugs of abuse? 3 The future of drugs of abuse? 4 NPS: from imitation to innovation ‘Designer drugs’ Party Herbal Research Legal pills highs chemicals highs ‘Legal highs’ Phenethylamines Tryptamines Piperazines Cathinones Synthetic CBs 1980s 1990s 2000s 2005 2008 Quest for new ‘ecstasy’ BZP Mephedrone Spice Who we are, what we do Factual, Objective, Reliable, Comparable Substances monitored by the EU EWS 2018: 55 >700 substances monitored in 13 categories (2005–2018): • >190 synthetic cannabinoids • >130 synthetic cathinones • ~50 opioids • >20 benzodiazepines 8 NPS detections in the EU More than 300,000 seizures of NPS reported by Synthetic cannabinoids and cathinones law enforcement from 2005–2016 account for almost 80% of all seizure cases reported in 2016 Almost 71,000 seizures of NPS in 2016 9 NPS quantities in the EU More than 24 tonnes of NPS seized by law enforcement from 2005–2016 Synthetic cannabinoids and cathinones accounted for 80% of all seizure cases and Just over 4 tonnes of NPS seized in quantities seized in 2016 2016 10 What caused the flood? 11 What caused the flood? China ▪ In 2015 almost 1.2 tonnes of the total quantity of NPS substances seized in the EU originated in China. -
Download Product Insert (PDF)
PRODUCT INFORMATION 4-ANPP Item No. 18810 CAS Registry No.: 21409-26-7 Formal Name: N-phenyl-1-(2-phenylethyl)-4- piperidinamine Synonyms: 4-Aminophenyl-1-phenethylpiperidine, N 4-Anilino-N-phenethylpiperidine, Despropionyl fentanyl H N MF: C19H24N2 FW: 280.4 Purity: ≥98% Supplied as: A neat solid Storage: -20°C Stability: ≥3 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Description 4-ANPP (Item No. 18810) is an analytical reference material categorized as an opioid metabolite and a precursor in the synthesis of fentanyl (Item Nos. ISO60197 | 22659 | 14719) and other opioids.1-4 4-ANPP is a metabolite of acetyl fentanyl (Item Nos. ISO60128 | ISO00128), butyryl fentanyl (Item Nos. 19734 | 14728), furanyl fentanyl (Item Nos. 19633 | 18705), acrylfentanyl (Item Nos. 23060 | 19312), and fentanyl.2-5 It has also been found as an impurity in illicit fentanyl preparations.6 4-ANPP is regulated as a Schedule II compound in the United States. This product is intended for research and forensic applications. This product is qualified as a Reference Material that has been manufactured and tested to ISO/IEC 17025 and ISO 17034 international standards. References 1. Pease, J.P., LePine, A.J., and Smith, C.M. Methods for preparing fentanyl and fentanyl intermediates. Patent Application Publication US 2013/0281702 A1, (2013). 2. Watanabe, S., Vikingsson, S., Roman, M., et al. In vitro and in vivo metabolite identification studies for the new synthetic opioids acetylfentanyl, acrylfentanyl, furanylfentanyl, and 4-fluoro-isobutyrylfentanyl. AAPS J. 19(4), 1102-1122 (2017). 3. Labroo, R.B., Paine, M.F., Thummel, K.E., et al. -
Lietuvos Respublikos Sveikatos Apsaugos Ministras
Elektroninio dokumento nuorašas LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTRAS ĮSAKYMAS DĖL LIETUVOS RESPUBLIKOS SVEIKATOS APSAUGOS MINISTRO 2003 M. BALANDŽIO 23 D. ĮSAKYMO NR. V-239 „DĖL NARKOTINIŲ IR PSICHOTROPINIŲ MEDŽIAGŲ NEDIDELIO, DIDELIO IR LABAI DIDELIO KIEKIO NUSTATYMO REKOMENDACIJŲ“ PAKEITIMO 2017 m. liepos 7 d. Nr. V-854 Vilnius P a k e i č i u Narkotinių ir psichotropinių medžiagų nedidelio, didelio ir labai didelio kiekio nustatymo rekomendacijas, patvirtintas Lietuvos Respublikos sveikatos apsaugos ministro 2003 m. balandžio 23 d. įsakymu Nr. V-239 „Dėl Narkotinių ir psichotropinių medžiagų nedidelio, didelio ir labai didelio kiekio nustatymo rekomendacijų“: 1. Papildau 121 punktu: „121. Alfa-metilfentanil butanamido analogas (Alpha- 0,0005 g 0,0035 g 0,02 g“ methylfentanyl butanamide analogue, 2-methyl-N- phenyl-N-[1-(1-phenylpropan-2-yl)piperidin-4- yl]propanamide) 2. Papildau 131 punktu: „131. Benzodioksole-fentanilis (Benzodioxole-fentanyl, BZD- 0,0005 g 0,0035 g 0,02 g“ F, benzodioxole-F, benzodioxolefentanyl, N-phenyl-N-[1- (2-phenylethyl)piperidin-4-yl]-2H-1,3-benzodioxole-5- carboxamide) 3. Papildau nauju 152 punktu: „152. Ciklopentilfentanilis (Cyclopentylfentanyl, Cyclopentyl- 0,0005 g 0,0035 g 0,02 g“ F, cyclopentyl-fentanyl, CP-F, N-phenyl-N-[1-(2- phenylethyl)piperidin-4-yl]cyclopentanecarboxamide, N- (1-phenethylpiperidin-4-yl)-N- phenylcyclopentanecarboxamide) 4. Buvusį 152 punktą laikau 153 punktu. 5. Papildau nauju 171 punktu: „171. 4F-BF (4-fluoro-butyrfentanyl, N-(4-fluorophenyl)-N-[(1- 0,0015 g 0,0105 g 0,06 g“ (2-phenylethyl)-4-piperidinyl)]butanamide) 6. Buvusius 171–173 punktus laikau atitinkamai 172–174 punktais. 7. Papildau 181 punktu: „181.